Table 3 Adverse events.

From: Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

Adverse eventa

Grade

All

1

2

3

N

N

N

N

Fatigue

7

3

4

.

Arthralgia

1

1

.

.

Oedema

2

2

.

.

Nausea/vomiting

3

3

.

.

Diarrhoea

2

1

1

.

Alkaline phosphatase increased

3

.

.

3

Aspartate aminotransferase increased

3

.

.

3

Other gastrointestinal (dry mouth, anorexia, bloating, rectal pain)

6

3

2

1

Hypercalcaemia

1

.

.

1

Hyperkalaemia

1

.

.

1

Hypothyroidism

1

.

1

.

Lymphocyte count decreased

2

.

2

.

Injection site reactions

1

1

.

.

Skin (rash, pruritis etc)

3

3

.

.

All

36

17

10

9

  1. aPossible, probable and definitely related to study drug (Highest grade for each toxicity per patient).
Back to article page